Trovagene Investor Relations Trovagene Investor Relations New Data from Phase 1b/2 Study of Onvansertib in Combination with LDAC or Decitabine Demonstrates Response to Treatment in Relapsed/Refractory AML - Preliminary Anti-Leukemic Activity Demonstrates >80% Response to Treatment with Onvansertib in Combination with Low-Dose Cytarabine (LDAC) or Decitabine in Dose Escalation Phase 1b of Trial Mon, 03 Dec 2018 08:00:00 -0800 Trovagene, Inc. Receives Positive Nasdaq Listing Decision Thu, 15 Nov 2018 05:30:00 -0800 Trovagene Announces Launch of New Company Website New website offers visitors greater insight into the Company's focus in oncology drug development, predictive clinical biomarkers and advances in Onvansertib clinical program Tue, 13 Nov 2018 05:30:00 -0800 Trovagene Announces Third Quarter 2018 Highlights and Financial Results Wed, 07 Nov 2018 13:20:00 -0800 Trovagene to Present Data from Lead Clinical Program of Onvansertib in Acute Myeloid Leukemia at the 60th American Society of Hematology Annual Meeting Targeted treatment with highly-selective, oral Polo-like Kinase 1 (PLK1) inhibitor, onvansertib, in combination with standard-of-care chemotherapy may represent a new treatment option in AML Thu, 01 Nov 2018 07:36:00 -0700